Literature DB >> 17368177

New insights into Vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model.

Mathew T Mizwicki1, Craig M Bula, June E Bishop, Anthony W Norman.   

Abstract

Recently, we have developed a Vitamin D sterol (VDS)-VDR conformational ensemble model. This model can be broken down into three individual, yet interlinked parts: (a) the conformationally flexible VDS, (b) the apo/holo-VDR helix-12 (H12) conformational ensemble, and (c) the presence of two VDR ligand binding pockets (LBPs); one thermodynamically favored (the genomic pocket, G-pocket) and the other kinetically favored by VDSs (the alternative pocket, A-pocket). One focus of this study is to use directed VDR mutagenesis to (1) demonstrate H12 is stabilized in the transcriptionally active closed conformation (hVDR-c1) by three salt-bridges that span the length of H12 (cationic residues R154, K264 and R402), (2) to elucidate the VDR trypsin sites [R173 (hVDR-c1), K413 (hVDR-c2) and R402 (hVDR-c3)] and (3) demonstrate the apo-VDR H12 equilibrium can be shifted. The other focus of this study is to apply the model to generate a mechanistic understanding to discrepancies observed in structure-function data obtained with a variety of 1alpha,25(OH)(2)-Vitamin D(3) (1,25D) A-ring and side-chain analogs, and side-chain metabolites. We will demonstrate that these structure-function conundrums can be rationalized, for the most part by focusing on alterations in the VDS conformational flexibility and the elementary interaction between the VDS and the VDR A- and G-pockets, relative to the control, 1,25D.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368177      PMCID: PMC1906717          DOI: 10.1016/j.jsbmb.2006.12.004

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  50 in total

Review 1.  Nuclear hormone receptors and gene expression.

Authors:  A Aranda; A Pascual
Journal:  Physiol Rev       Date:  2001-07       Impact factor: 37.312

2.  Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands.

Authors:  G Tocchini-Valentini; N Rochel; J M Wurtz; A Mitschler; D Moras
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

3.  Enhanced biological activity of 1alpha,25-dihydroxy-20-epi-vitamin D3, the C-20 epimer of 1alpha,25-dihydroxyvitamin D3, is in part due to its metabolism into stable intermediary metabolites with significant biological activity.

Authors:  M L Siu-Caldera; H Sekimoto; S Peleg; C Nguyen; A M Kissmeyer; L Binderup; A Weiskopf; P Vouros; M R Uskoković; G S Reddy
Journal:  J Steroid Biochem Mol Biol       Date:  1999-12-15       Impact factor: 4.292

4.  Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor.

Authors:  H Harant; D Spinner; G S Reddy; I J Lindley
Journal:  J Cell Biochem       Date:  2000-04       Impact factor: 4.429

5.  Characterization of a novel analogue of 1alpha,25(OH)(2)-vitamin D(3) with two side chains: interaction with its nuclear receptor and cellular actions.

Authors:  A W Norman; P S Manchand; M R Uskokovic; W H Okamura; J A Takeuchi; J E Bishop; J I Hisatake; H P Koeffler; S Peleg
Journal:  J Med Chem       Date:  2000-07-13       Impact factor: 7.446

6.  Synthesis, biological evaluation, and conformational analysis of A-ring diastereomers of 2-methyl-1,25-dihydroxyvitamin D(3) and their 20-epimers: unique activity profiles depending on the stereochemistry of the A-ring and at C-20.

Authors:  K Konno; T Fujishima; S Maki; Z Liu; D Miura; M Chokki; S Ishizuka; K Yamaguchi; Y Kan; M Kurihara; N Miyata; C Smith; H F DeLuca; H Takayama
Journal:  J Med Chem       Date:  2000-11-02       Impact factor: 7.446

7.  Metabolism of 1alpha,25-dihydroxyvitamin D(3) in human promyelocytic leukemia (HL-60) cells: in vitro biological activities of the natural metabolites of 1alpha,25-dihydroxyvitamin D(3) produced in HL-60 cells.

Authors:  D S Rao; M J Campbell; H P Koeffler; S Ishizuka; M R Uskokovic; P Spagnuolo; G S Reddy
Journal:  Steroids       Date:  2001 Mar-May       Impact factor: 2.668

Review 8.  Highly active analogs of 1alpha,25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways.

Authors:  M R Uskokovic; A W Norman; P S Manchand; G P Studzinski; M J Campbell; H P Koeffler; A Takeuchi; M L Siu-Caldera; D S Rao; G S Reddy
Journal:  Steroids       Date:  2001 Mar-May       Impact factor: 2.668

9.  Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation.

Authors:  B A Johnson; E M Wilson; Y Li; D E Moller; R G Smith; G Zhou
Journal:  J Mol Biol       Date:  2000-04-28       Impact factor: 5.469

10.  Vitamin D receptor agonists specifically modulate the volume of the ligand-binding pocket.

Authors:  Ferdinand Molnár; Mikael Peräkylä; Carsten Carlberg
Journal:  J Biol Chem       Date:  2006-02-13       Impact factor: 5.157

View more
  11 in total

1.  A molecular description of ligand binding to the two overlapping binding pockets of the nuclear vitamin D receptor (VDR): structure-function implications.

Authors:  Mathew T Mizwicki; Danusa Menegaz; Sepideh Yaghmaei; Helen L Henry; Anthony W Norman
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-14       Impact factor: 4.292

2.  Vitamin D controls T cell antigen receptor signaling and activation of human T cells.

Authors:  Marina Rode von Essen; Martin Kongsbak; Peter Schjerling; Klaus Olgaard; Niels Odum; Carsten Geisler
Journal:  Nat Immunol       Date:  2010-03-07       Impact factor: 25.606

3.  A human vitamin D receptor mutant activated by cholecalciferol.

Authors:  Amanda M Ousley; Hilda S Castillo; Anna Duraj-Thatte; Donald F Doyle; Bahareh Azizi
Journal:  J Steroid Biochem Mol Biol       Date:  2011-03-10       Impact factor: 4.292

4.  On the mechanism underlying (23S)-25-dehydro-1alpha(OH)-vitamin D3-26,23-lactone antagonism of hVDRwt gene activation and its switch to a superagonist.

Authors:  Mathew T Mizwicki; Craig M Bula; Paween Mahinthichaichan; Helen L Henry; Seiichi Ishizuka; Anthony W Norman
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

5.  1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients.

Authors:  Mathew T Mizwicki; Guanghao Liu; Milan Fiala; Larry Magpantay; James Sayre; Avi Siani; Michelle Mahanian; Rachel Weitzman; Eric Y Hayden; Mark J Rosenthal; Ilka Nemere; John Ringman; David B Teplow
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

6.  Agonist and antagonist binding to the nuclear vitamin D receptor: dynamics, mutation effects and functional implications.

Authors:  Sepideh Yaghmaei; Christopher Roberts; Rizi Ai; Mathew T Mizwicki; Chia-En A Chang
Journal:  In Silico Pharmacol       Date:  2013-02-12

7.  The conformational dynamics of H2-H3n and S2-H6 in gating ligand entry into the buried binding cavity of vitamin D receptor.

Authors:  Wei-Ven Tee; Adiratna Mat Ripen; Saharuddin Bin Mohamad
Journal:  Sci Rep       Date:  2016-10-27       Impact factor: 4.379

8.  Functional Analysis of VDR Gene Mutation R343H in A Child with Vitamin D-Resistant Rickets with Alopecia.

Authors:  Min-Hua Tseng; Shih-Ming Huang; Fu-Sung Lo; Jing-Long Huang; Chih-Jen Cheng; Hwei-Jen Lee; Shih-Hua Lin
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

Review 9.  The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control.

Authors:  F C Campbell; Haibo Xu; M El-Tanani; P Crowe; V Bingham
Journal:  Biochem Pharmacol       Date:  2009-09-06       Impact factor: 5.858

10.  An alternate binding site for PPARγ ligands.

Authors:  Travis S Hughes; Pankaj Kumar Giri; Ian Mitchelle S de Vera; David P Marciano; Dana S Kuruvilla; Youseung Shin; Anne-Laure Blayo; Theodore M Kamenecka; Thomas P Burris; Patrick R Griffin; Douglas J Kojetin
Journal:  Nat Commun       Date:  2014-04-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.